Sabel Michael S
Division of Surgical Oncology, University of Michigan Comprehensive Cancer Center, Department of Surgery, 3304 Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA.
Cryobiology. 2009 Feb;58(1):1-11. doi: 10.1016/j.cryobiol.2008.10.126. Epub 2008 Oct 17.
The use of cryosurgery to ablate tumors is expanding, primarily due to its technical ease and minimal morbidity. A potential secondary advantage to the in situ freezing of malignant disease is the cryo-immunologic response, the generation of an anti-tumor immune response triggered by the natural absorption of the malignant tissue. While initially proposed based on clinical observations of distant disease regressing after cryoablation of a primary tumor, results from preclinical studies have been mixed and the existence of a cryo-immunologic response has been controversial. Recent studies have shed light on the potential mechanism by which cryoablation may modulate the immune system, also reveals that both immunostimulatory and immunosuppressive responses may be triggered. This article reviews the existing evidence regarding tumor cryo-immunology and puts forward hypotheses regarding patient, tumor and technical factors that may influence the resultant immune response and warrant further investigation.
冷冻手术用于消融肿瘤的应用正在不断扩大,这主要归因于其操作技术简便且发病率极低。原位冷冻恶性疾病的一个潜在次要优势是冷冻免疫反应,即由恶性组织的自然吸收引发的抗肿瘤免疫反应。虽然最初是基于对原发性肿瘤进行冷冻消融后远处疾病消退的临床观察提出的,但临床前研究的结果参差不齐,冷冻免疫反应的存在一直存在争议。最近的研究揭示了冷冻消融可能调节免疫系统的潜在机制,也表明免疫刺激和免疫抑制反应都可能被触发。本文回顾了关于肿瘤冷冻免疫学的现有证据,并提出了关于可能影响最终免疫反应并值得进一步研究的患者、肿瘤和技术因素的假设。